Business
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications.\n\"We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs will serve us well as we look to execute on the opportunities ahead of us.\"\n\"I am excited by the opportunities that Karyopharm has to positively impact the lives of patients through our late-stage pipeline, building on our core foundation in multiple myeloma,\" said Brendan Strong, Senior Vice President of Investor Relations and Corporate Communications. \"The upcoming year represents a transformative time for our organization and I look forward to advancing our mission.\"\nMost recently, Brendan served as Managing Director at Argot Partners where he advised biopharmaceutical companies on their investor relations and corporate communications programs. Previously, Brendan led investor relations for Tenet Healthcare and also served as Chief Financial Officer of Tenet's Massachusetts Market. Earlier in his career, he worked in the equity research department at Lehman Brothers and Barclays and also participated in a financial leadership training program at AT&T.\nBrendan earned an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.\nAbout Karyopharm TherapeuticsKaryopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncolog...